INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHY

Abstract

Intravitreal ranibizumab appeared to result in stabilization of vision in patients with symptomatic polypoidal choroidal vasculopathy. However, combined ranibizumab and PDT appeared to be more effective in causing complete regression of the polypoidal lesions in indocyanine green angiography compared with ranibizumab monotherapy.